In This Section

Program

Please note that this meeting will take place as an in-person event in Austin and will not live-stream content for virtual participation. The meeting content will be recorded and made available as an on-demand program after the conference.

All presentations are scheduled to be live, in-person presentations at the date and time specified below unless noted otherwise.  Program in progress.

[R] – Remote Presentation

Monday, January 23, 2023

Welcome and Keynote Lectures

Tuesday, January 24, 2023

Plenary Session 1: Apoptosis
Plenary Session 2: Stem Cells
Plenary Session 3: Epigenetics
Plenary Session 4: Niche/Microenvironment
Plenary Session 5: Splicing Mutations

Wednesday, January 25, 2023

Plenary Session 6: Minimal Residual Disease
Plenary Session 7: Inflammation
Plenary Session 8: Cell and Immune Targeting in Myeloid Malignancies

Monday, January 23, 2023

Welcome and keynote lectures
5-6:30 p.m.   

Understanding and targeting altered RNA splicing in MDS and AML
Omar Abdel-Wahab, Memorial Sloan Kettering Cancer Center, New York, New York 

Germline predisposition to myeloid malignancies
Lucy A. Godley, University of Chicago, Chicago, Illinois

Poster Session A/Opening Reception  
6:45-9 p.m.  

Tuesday, january 24, 2023

Continental Breakfast 
7-8 a.m. 
Plenary Session 1: Apoptosis
Session Chair: To Be Announced
8-9:35 a.m. 

Inducing apoptosis in leukemia stem cells by targeting metabolism
Courtney L. Jones, Princess Margaret Cancer Centre, University Health Network,
Toronto, Ontario, Canada

Understanding and preventing resistance to BCL2 inhibitor therapy in AML
Courtney D. DiNardo, The University of Texas MD Anderson Cancer Center, Houston, Texas 

Title to be announced
Zaneta Nikolovska-Coleska, University of Michigan, Ann Arbor, Michigan

Panel Discussion

Break 
9:35-9:55 a.m.
Plenary Session 2: STEM CELLS
Session Chair: Ravi Majeti, Stanford University, Stanford, CAlifornia
9:55-11:30 a.m.

Title to be announced
Monica L. Guzman, Weill Cornell Medicine, New York, New York 

Title to be announced
Eric R. Lechman, UHN-Toronto General Hospital, Toronto, ON, Canada

Stem cells in human AML
Ravi Majeti, Stanford University, Stanford, California

Panel Discussion

Break
11:30-11:50 a.m.
Plenary Session 3: Epigenetics 
Session Chair: To Be Announced
11:50 a.m.-1:25 p.m.

Epigenetic deregulation in myeloid malignancies
Maria (Ken) Figueroa, University of Miami, Miami, Florida 

Title to be announced
Luisa Cimmino, University of Miami Miller School of Medicine, Miami, Florida 

Title to be announced
Jian Xu, UT Southwestern Medical Center, Dallas, Texas 

Lunch on own/free time
1:25-3:15 p.m.
Plenary Session 4:  NICHE/MICROENVIRONMENT 
Session Chair: To Be Announced
3:15-5:15 p.m.

Dissecting the cross-talk between normal, leukaemic stem cells, and the bone marrow microenvironment [R]
Dominique Bonnet, The Francis Crick Institute, London, England

Title to be announced
Simón Méndez-Ferrer, University of Cambridge, Cambridge, England

Anatomy of normal and leukemic hematopoiesis in the bone marrow
Daniel Lucas, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio

Interactions with the immune microenvironment in MDS and AML
Iannis Aifantis, NYU Langone Health, New York, New York

Panel Discussion

Break 
5:15-5:30 p.m.
Plenary Session 5:  Splicing Mutations  
5:30-7:05 p.m.

Therapeutic targeting of the Rbm39 splicing factor in immunity
Sydney X. Lu, Memorial Sloan Kettering Cancer Center, New York, New York 

Targeting SF3B1 in myelodysplastic syndromes
Esther A. Obeng, St. Jude Children’s Research Hospital, Memphis, Tennessee

Genetic factors mediating pre-malignant clonal expansion
Siddhartha Jaiswal, Stanford University, Stanford, California

Panel Discussion  

Evening off/dinner on own
7:05 p.m.

Wednesday, January 25, 2022

Continental Breakfast
7-8 a.m.
Plenary Session 6: Minimal Residual Disease 
8-9:35 a.m.

Measurable residual disease in AML: A roadmap for evidence and implementation
Christopher S. Hourigan, National Heart, Lung and Blood Institute, Bethesda, Maryland

Measurable residual disease assessment for lower intensity therapy in AML
Farhad Ravandi-Kashani, The University of Texas MD Anderson, Houston, Texas 

Title to be announced
Cihangir Duy, Fox Chase Cancer Center, Philadelphia, Pennsylvania

Panel Discussion

Break
9:35-9:55 a.m.
Plenary Session 7: Inflammation 
9:55-11:30 a.m. 

Inflammation and the MPNs: From phenotype to therapy
Ruben A. Mesa, Mays Cancer Center at UT Health San Antonio, San Antonio, Texas 

Title to be announced
Daniel T. Starczynowski, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio

Title to be announced
Serine Avagyan, Dana-Farber Cancer Institute, Boston, Massachusetts

Panel Discussion

Break 
11:30-11:45 a.m.
Plenary Session 8: Cell and Immune Targeting in Myeloid Malignancies 
11:45 a.m.–1:20 p.m. 

Graft versus Leukemia (GvL): Identification and characterisation of alloreactive antigens and cognate T cell responses in Acute Myeloid Leukemia
Paresh Vyas, University of Oxford, Oxford, United Kingdom 

Title to be announced
Gerhard Ehninger, AvenCell Europe GmbH, Dresden, Germany

Title to be announced
Xianxin Hua, Penn Medicine Abramson Cancer Center, Philadelphia, Pennsylvania

Panel Discussion 

Closing remarks
1:20 p.m.